Objectives: This study investigated the PKCa protein expression in gastric carcinoma, and correlated it with clinicopathological parameters. The prognostic significance of PKCa protein expression in gastric carcinoma was analyzed.
Introduction
Gastric cancer is the fourth most common cancer worldwide, and the second leading cause of cancer death in men and the fourth in women [1, 2] . Although surgical techniques and adjuvant chemotherapy have substantially improved recently and rate of early detection by endoscopy has increased, the overall 5-year survival rate remains dismal [1] . A steady decline in gastric cancer incidence has been observed in most developed countries and some developing countries over the past 50 years [2] . However, gastric cancer remains a major public health problem throughout the world. The carcinogenesis of gastric carcinoma is not well understood, but it exhibits a multi-hit process of genetic alterations involving suppressor genes and oncogenes [3, 4] .
The protein kinase C (PKC) family consists of serine-threonine kinases that act by phosphorylating their specific protein substrates. The PKC family members are classified into three major groups: classical (a, b, and c), novel (d, e, g, and h), and atypical (m, l, j). Activation of classical PKCs depends on calcium and phospholipids. Novel PKCs are activated by phospholipids, and activation of atypical forms occurs independently of calcium or phospholipids. PKCs are involved in various cellular processes including regulating gene expression, proliferation, differentiation, apoptosis, migration, and tumor development [5] [6] [7] [8] [9] [10] . Because of the existence of many PKC isoforms and their involvement in different cellular signaling pathways, the roles of PKC isoforms in carcinogenesis have not been clarified [8] .
Among the PKC isoforms, PKCa is ubiquitously expressed in many tissues and has been associated with cell proliferation, apoptosis, and cell motility. PKCa activation results in increased cell motility and invasiveness in in vivo and in vitro cancer models [8] . PKCa has been found to be the most important PKC isoform in the formation and progression of malignancies in various cell lines [11] . Abnormal levels of PKCa have been found in transformed cell lines and human cancers [12] . Substantial evidence from gene knockout studies indicates that PKCa activity regulates cancer growth and progression. Selective targeting of PKCa thus has a potential therapeutic role in a wide variety of human cancers [13] .
The specific role of PKCa in gastrointestinal tumors has not been well studied [14] . Among the PKC family, PKCa is the most abundant isoform in gastric epithelia, and might play an important role in the carcinogenesis and metastasis of gastric cancers [10] . Furthermore, PKCa is known to play a critical role in cancer cell proliferation and in maintaining the transformed phenotype and tumorigenic capacity of gastric cancer cells [10, 14] . Our previous study using quantitative real-time PCR tests demonstrated that in gastric carcinoma, PKCa mRNA overexpression was correlated with distant metastasis, and might be an independent prognostic marker [15] . However, the expression of PKCa protein in gastric carcinoma and its clinicopathological correlations have not been investigated. Our study thus evaluated the expression of PKCa protein in gastric carcinoma using immunohistochemical method. The aims of this study were to assess the expression of PKCa protein in gastric carcinoma, and to correlate it with other clinicopathological parameters. The prognostic significance of PKCa protein overexpression in gastric carcinoma was also investigated.
Materials and Methods
We collected 215 consecutive cases of gastric carcinoma from the medical files of both Wan-Fang Hospital and Taipei Medical University Hospital in Taiwan. All patients included in our study group were treated between 1997 and 2011, and had received surgical resection with radical total or subtotal gastrectomy and lymph node dissection. All pathological reports and hematoxylin & eosin sections were available and reviewed to determine pathological parameters including tumor size, location, histologic type, differentiation, depth of invasion, angiolymphatic invasion, nodal status, local recurrence status, distant metastasis, and pathologic staging. The pathologic staging was based on the 7th edition of the TNM staging system of AJCC. For each case, one or more representative sections and corresponding blocks of both tumorous and non-tumorous tissues were retrieved for immunohistochemical study. From the patients' records, we obtained the information including postoperative courses, tumor recurrence, distant metastasis, and outcome. This study received ethical approval from the institutional review board of Taipei Medical University. Written informed consent was obtained from each participant before tissue acquisition.
Quantitative Real-Time PCR Test
At first quantitative real-time PCR test was applied to test and compare the mRNA expression of PKCa in tumorous and nontumorous tissues of gastric carcinoma in a small scale. Ten tumor and non-tumor pairs of gastric tissues were randomly selected from the Tumor and Serum Bank of Chi-Mei Medical Center (Tainan, Taiwan). All samples were collected from the specimens via radical gastrectomy. The non-tumor part was taken from the grossly normal gastric mucosa away from the tumor. All tissues were frozen in liquid nitrogen within 20 min and kept at -80uC until use.
The procedure of quantitative real-time PCR test was performed according to previous study [15] .
Immunohistochemical Study
Sections of 5 mm thickness were taken from formalin-fixed paraffin-embedded blocks. The procedure of immunohistochemical study was performed according to previous study [15] . Deparaffinized sections were incubated in pH 6.0 citrate buffer for 40 min at 95uC on a hotplate to retrieve the antigens. Endogenous peroxidase was blocked by 3% hydrogen peroxide for 5 min. The sections were subsequently incubated with antibody against PKCa (Santa Cruz Biotechnology Inc., Santa Cruz, CA, SC-8393) for 30 min at room temperature at a dilution of 1:100 using DAKO primary antibody diluent. To detect immunoreactivity, the avidinbiotin-complex method was applied according to the manufacturer's instructions. A sensitive Dako EnVision kit (Dako North America Inc., Carpinteria, CA) was used as the detection system. After incubation with secondary antibody (DAKO EnVision) for 30 min at room temperature, followed by diaminobenzidine for 8 min, sections were counterstained with Mayer's hematoxylin. Normal human distal renal tubules were used as a positive control. The negative control was made by omitting the primary antibody and incubation with PBS.
The PKCa immunoreactivity was evaluated independently by two pathologists (CL Fang and SE Lin). As in previous studies [16, 17] , the results were scored semiquantitatively in four categories: 0 = absent, 1 = weak, 2 = moderate, and 3 = strong immunoreactivity. The positive staining of nerve bundles in the same slide was used as the positive internal control and was allocated score 2. The negative control provided a reference of score 0. Score 1 was defined as positive staining that was weak compared with internal control; score 3 was allocated to positive staining stronger than that of internal control. Finally each case was assigned to one of two groups: either PKCa overexpression with score 2 or 3, or non-overexpression with score 0 or 1.
Statistical Analysis
All data were analyzed using the SAS software (Version 9.2 SAS Institute Inc., Cary, NC). Chi-square tests and correlation coefficient analysis were performed to determine whether the correlations between PKCa overexpression and other clinicopathological parameters were statistically significant. The cumulative overall survival rates and disease free survival rates were calculated by the Kaplan-Meier method, and the differences in survival rates between PKCa overexpression and non-expression groups were analyzed by a log-rank test. To determine the relative prognostic impact of PKCa overexpression compared with other established prognostic markers, overall survival was analyzed using the Cox proportional hazard model. For uni and multivariate Cox regression analysis, continuous variables were coded as binary variables. Backward multivariate analysis was also applied to identify independent prognostic markers. All tests were performed with the significance level at P,0.05.
Results

PKCa mRNA Expression was Upregulated in Gastric Carcinoma
In all ten tumor and non-tumor pairs of gastric tissues randomly selected for quantitative real-time PCR, the mRNA expression of PKCa in tumor tissues were substantially increased when compared to non-tumor tissues (Table 1) .
Basic Data for Immunohistochemical Study
Data from a total of 215 cases of gastric carcinoma were analyzed. The patients included 134 men and 81 women, with a mean age of 69 years (range 30 years to 96 years). Among the 215 cases, 52 patients had the disease at stage I, 43 patients at stage II, 98 patients at stage III, and 22 patients at stage IV. Postoperative clinical follow-up and survival analysis were recorded in all 215 patients. The follow-up period ranged from 5 days to 5131 days (mean 1143 days). Distant metastasis status was obtained in all patients, of whom 67 had metastatic diseases.
PKCa Protein Expression was Upregulated in Gastric Carcinoma
Of the total 215 cases of gastric carcinoma, 88 patients (41%) revealed PKCa protein overexpression. The intensity and distribution of immunoreactivity varied among the PKCa-positive cases, and immunoreactivity was observed in the cytoplasm of the tumor cells. In all cases, the normal gastric glands in non-tumor tissues revealed negative staining (Fig. 1a) . Overexpression of PKCa protein was observed in tumor cells but not in normal gastric glands, with the difference being statistically significant (McNemar test, P,0.001).
Overexpression of PKCa Protein Was Statistically
Correlated with Age, Histologic Type, Tumor Differentiation, Depth of Invasion, Angiolymphatic Invasion, Pathologic Stage, and Distant Metastasis A Chi-square test was performed to determine the significance of the difference between PKCa overexpression and other clinicopathological parameters (Table 2) . PKCa protein overexpression was statistically correlated with age. Patients aged 60 years or older had a higher rate of PKCa protein overexpression (46%) than those of less than 60 years (25%). There was a statistically significant correlation between PKCa protein overexpression and histologic type (P,0.0001). Among 137 cases of intestinal type carcinoma, 71 cases (52%) showed PKCa protein overexpression. In contrast, only 17 out of 78 cases (22%) of diffuse type carcinoma showed PKCa protein overexpression. In addition, overexpression of PKCa protein was significantly statistically correlated with tumor differentiation (P = 0.0110). Among the 112 cases of well to moderately-differentiated carcinoma, 55 (49%) displayed PKCa protein overexpression. However, among the 103 cases of poorly-differentiated carcinoma, only 33 (32%) exhibited PKCa protein overexpression. Our data thus revealed that well to moderately-differentiated intestinal type tumors more frequently expressed PKCa protein than those of the diffuse type. The PKCa immunostaining patterns of various histologic type and tumor differentiation are shown in Figs. 1b to 1i. A statistical significance was also noticed between PKCa protein overexpression and depth of tumor invasion. In 66 cases of T1 and T2 tumor (invasion not beyond muscularis propria), 39 (59%) presented PKCa protein overexpression. In contrast, 49 out of 149 cases (33%) of T3 and T4 tumor (invasion of subserosa or deeper) displayed PKCa protein overexpression. Also found is a statistic significance between PKCa protein overexpression and angiolymphatic invasion. There were 135 cases with angiolymphatic invasion and 80 cases with no invasion. The PKCa protein overexpression rates were 36% in the former and 50% in the latter, respectively. The tumors with vascular emboli had lower PKCa protein overexpression rate than those with no emboli. Overexpression of PKCa protein has a statistical correlation with pathologic stage. Among the 95 stage I and II cases, there were 49 (52%) with PKCa protein overexpression. In 120 cases at stage III and IV, only 39 (33%) revealed PKCa protein overexpression. We observed that early stage tumors were likely to express PKCa protein than tumors with advanced stage. Finally, there was a significantly statistical correlation between PKCa protein overexpression and distant metastasis. Eighteen out of 67 cases (27%) with distant metastasis showed overexpression of PKCa protein, and 70 out of 148 cases (47%) with no distant metastasis possessed PKCa protein overexpression. Therefore, PKCa protein overexpression was negatively statistically correlated with distant metastasis. In addition, correlation coefficients were calculated. The correlation coefficient (r) and P value (P) in statistically significant variables were as follows: age (r = 0.16301; P = 0.0167), histologic type (r = -0.29364; P,0.0001), tumor differentiation (r = -0.17341; P = 0.0109), depth of invasion (r = -0.24581; P = 0.0003), angiolymphatic invasion (r = -0.14199; P = 0.0375), pathologic stage (r = -0.19269; P = 0.0046), and distant metastasis (r = -0.19245; P = 0.0046).
No statistical significance was found between PKCa protein overexpression and other clinicopathological parameters including gender, tumor size, location, lymph node status, and local recurrence.
The Expression of PKCa Protein Was a Significant Independent Prognostic Factor in Multivariate Cox Regression Analysis
The data of 215 patients were enrolled for survival analysis. The overall survival rate among the 88 patients with PKCa protein overexpression was 64%, and among the 127 without overexpression was 47%. We also analyzed disease free survival. In PKCa protein overexpression group and non-overexpression group, the disease free survival rates were 58% and 42%, respectively. The difference in overall and disease free survival rates between the PKCa overexpression and non-overexpression groups was not statistically significant (log rank test P = 0.0680 and 0.0587), but did indicate a tendency for patients with PKCa protein overexpression to have a longer overall survival and disease free survival than those lacking overexpression. The univariate Cox regression analysis of prognostic markers is summarized in Table 3 . The overall survival was statistically correlated with age, tumor size, histologic type, tumor differentiation, depth of invasion, angiolymphatic invasion, nodal status, pathologic staging, local recurrence, and distant metastasis. PKCa protein overexpression was not statistically correlated with overall survival in univariate analysis (P = 0.0699). However, backward multivariate Cox regression analysis found that PKCa protein overexpression was an independent prognostic marker for overall survival. Patients in the overexpression group had a statistically significant longer overall survival rate compared with patients in the non-expression group (hazard ratio 0.632; 95% confidence interval 0.407-0.982; P = 0.0415) ( Table 4 ). Other co-variables of prognosis included age, pathologic stage, local recurrence, and distant metastasis.
Discussion
The protein kinase C (PKC) family consists of serine-threonine kinases that act by phosphorylating specific protein substrates. PKCs are involved in regulating gene expression, proliferation, apoptosis, and migration [5] . Different PKC isoforms display cell specific patterns of distribution that reflect a variety of role of isoforms [18] . PKCa is the most important PKC isoform for the formation and progression of malignancies in various cell lines [11] , and abnormal PKCa levels are found in many transformed cell lines [14] . PKCa acts as a tumor promoter in some tumors, but it functions as a tumor suppressor in others [13] . PKCa expression and its role in tumorigenesis and tumor progression have been documented in human cancers. PKCa overexpression has been reported in prostate carcinoma, endometrial carcinoma, high-grade bladder urothelial carcinoma, and hepatocellular carcinoma. The up-or downregulation of PKCa has been described in hematological malignancies [8] , and PKCa downregulation has been observed in basal cell carcinoma and colon carcinoma [8, [19] [20] [21] . One study reported the activation of PKCa in breast cancer [22] , whereas other studies have demonstrated the downregulation of PKCa protein in breast cancer [8, 13, 17] . PKCa inhibits cell growth in normal intestinal epithelial cells and pancreatic carcinoma [19] . Thus the expression patterns of PKC isoforms differ across different tissues and even within the same tissue [23] . To date, the role of PKCa expression in human cancers is not well understood, but seems to depend on tumor type.
PKCa has been hypothesized to play an important role in the carcinogenesis and metastasis of gastrointestinal cancers. PKCa protein is the most abundant isoform in gastric epithelial cells [10] , although the role of PKCa in gastrointestinal tumors is not clear. With regard to intestinal cancer, one study has postulated that PKCa acts as a tumor suppressor [9] , but another study has indicated that PKCa may act as both a tumor promoter and tumor suppressor [24] . In colon carcinoma, PKCa overexpression has been correlated with the migratory activity of tumor cells [23] . The first report to document the critical role of PKCa in maintaining the transformed phenotype of gastric cancer cells was published in 2004 [10] . Another study showed that PKCa promotes apoptosis of MGC80-3 gastric cancer cells [25] . Recently, we postulated that PKCa mRNA expression is upregulated, and is associated with distant metastasis in gastric carcinoma [15] . Several immunohistochemical studies have demonstrated that PKCa is overexpressed in high-grade bladder, prostate, and endometrial cancers, whereas breast, colon, and basal cell cancers display downregulation of PKCa expression [21] . Although an association between PKCa expression and gastric carcinoma has been documented, neither the clinicopathological correlations nor the prognostic significance of PKCa protein overexpression in gastric carcinoma had been studied. In this study, we tested the PKCa mRNA expression in gastric carcinoma at first via quantitative real-time PCR using ten pairs of tumor and nontumor gastric tissues. Our data demonstrated PKCa mRNA expression was upregulated in gastric carcinoma. Then we applied immunohistochemical method to evaluate the expression of PKCa protein in gastric carcinomas. Our data indicated PKCa protein overexpression in 41% cases of gastric carcinoma. Furthermore, PKCa protein overexpression was correlated to clinicopathological parameters. We found PKCa protein overexpression to be statistically correlated with histologic type. Intestinal type tumors more frequently expressed PKCa protein than did diffuse type tumors. According to general concept of gastric carcinogenesis, intestinal type and diffuse type carcinomas appear to evolve through different pathways, involving different oncogenes and tumor suppressor genes [26] . Gene expression profiling studies have shown that diffuse type carcinoma exhibits an altered expression of genes related to cell-matrix interaction and extracellular-matrix components, whereas intestinal type carcinoma exhibits enhanced cell growth [27] . Thus we conduct that PKCa protein plays a role in gastric carcinogenesis, especially intestinal type carcinoma.
We also found PKCa protein overexpression to be statistically correlated with tumor differentiation. Well to moderately-differentiated tumors more frequently expressed PKCa protein than did poorly-differentiated ones. The association between PKCa activity and tumor differentiation and/or histological grading has been reported for various malignancies. In superficial bladder cancer, abnormally activated PKCa may play a role in tumor differentiation, and elevated PKCa activation correlates with higher histological grade [28] . PKCa is highly expressed in poorlydifferentiated hepatocellular carcinoma cell lines [11] . In melanomas, PKCa activation is typically associated with decreased differentiation [12] . PKCa expression is elevated in high-grade endometrial tumors [19] . In breast cancer, expression of PKCa correlates with high histological grade and proliferation rate [17] . By contrast, one study reported that ovarian carcinoma exhibited decreasing in PKCa expression with increasing histological grade [29] . We found PKCa protein overexpression to be associated with histological grade and tumor differentiation in gastric carcinoma. In addition, we found that PKCa-positive high-grade dysplastic glands, precursor lesions of intestinal type carcinoma, were frequently observed in intestinal type carcinomas with PKCa protein overexpression. The PKCa protein is thus thought to be involved in the early stage of gastric carcinogenesis.
PKCa has been thought to play an important role in tumor progression. It has been implicated in several cancer-related processes, such as invasion and metastasis [10] . The role of PKCa in regulating tumor growth and development is clearly complex and highly tissue-dependent. In some cases PKCa acts as a tumor promoter, and in others it functions as a tumor suppressor [13] . In current immunohistochemical study, expression of PKCa protein was negatively statistically correlated to depth of invasion, angiolymphatic invasion, pathologic stage, and distant metastasis. We thus conduct that PKCa protein acts as a tumor suppressor, and downregulates gastric carcinoma progression.
PKCa has been reported to be a prognostic marker in human cancers. In Kong's study, high level PKCa predicted a shortened recurrence-free survival in patients with superficial bladder carcinomas [28] . Haughian et al demonstrated that PKCa level may be a prognostic indicator of aggressive endometrial cancers [19] . Patients with higher PKCa mRNA expression in hepatocellular carcinomas have a significantly decreased survival rate [21] . For patients with breast cancer, the prognostic significance of PKCa is controversial. Lønne et al reported that patients with PKCa-positive breast carcinoma had a poorer survival rate [17] , but Kerfoot et al found that PKCa was downregulated in advanced breast carcinoma [16] . Although no statistical significance via Kaplan-Meier method, our study showed a tendency for patients with PKCa protein overexpression to have a longer overall survival and disease free survival than those without overexpression. Furthermore, we found that PKCa protein overexpression was a significant independent prognostic factor for gastric carcinoma in multivariate analysis. Patients with PKCa protein overexpression had a statistically significant longer survival period.
In our previous study, we demonstrated that PKCa mRNA expression was upregulated and associated with distant metastasis in gastric carcinoma, and that PKCa mRNA overexpression predicted poor outcome [15] . Considering the results of that study together with those of the current one, we concluded that in patients with advanced gastric carcinomas, PKCa mRNA plays a promoting role in decreased survival, whereas PKCa protein has an opposing effect to suppress cancer progression and decrease cancer mortality. Several hypotheses might account for this finding. First, PKCa protein is subjected to complete proteolysis during or preceding late-stage gastric cancers. A previous study has documented that the activation and degradation of PKC isoforms were controlled spatially and temporally [30] . Second, post-transcriptional processing and RNA splicing might be responsible for the opposite effects of mRNA versus the protein of PKCa. In addition, the catalytically-competent PKCa molecules in cells are tightly regulated by phosphorylation, cofactor binding, and intracellular localization. PKCa biological activity is modulated by and functionally interacts with a number of protooncogenes. The PKCa molecules must be processed by a series of phosphorylation to attain catalytic competence. Undergoing translocation to the plasma membrane, PKCa is activated and consequently carries out substrate phosphorylation. After this, phosphorylated PKCa resides in the cytoplasm of the cell and requires additional regulatory mechanisms to become fully catalytically active [7, 16] . Therefore, PKCa protein expression might not fully represent kinase activity. In addition, immunoreactivity might not fully reflect true protein expression [31] . Further studies using kinase activity assay, immunogold labeling to identify subcellular localization and translocation of PKCa protein, and fluorescence in situ hybridization to detect PKCa mRNA in different pathological stages of gastric carcinoma are needed to clarify the discrepant roles of protein and mRNA of PKCa.
In conclusion, we demonstrated that PKCa protein is upregulated in gastric carcinoma. PKCa protein expression was statistically correlated with age, histologic type, tumor differentiation, depth of invasion, angiolymphatic invasion, pathologic stage, and distant metastasis. The PKCa protein overexpression was a significant independent prognostic factor for patients with gastric carcinoma in multivariate Cox regression analysis.
